Literature DB >> 24658822

Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.

Giovanni F Torelli1, Nadia Peragine2, Sara Raponi2, Daria Pagliara3, Maria S De Propris2, Antonella Vitale2, Alice Bertaina3, Walter Barberi2, Lorenzo Moretta4, Giuseppe Basso5, Angela Santoni6, Anna Guarini2, Franco Locatelli7, Robin Foà2.   

Abstract

In this study, we aimed to investigate the pathways of recognition of acute lymphoblastic leukemia blasts by natural killer cells and to verify whether differences in natural killer cell activating receptor ligand expression among groups defined by age of patients, or presence of cytogenetic/molecular aberrations correlate with the susceptibility to recognition and killing. We analyzed 103 newly diagnosed acute lymphoblastic leukemia patients: 46 adults and 57 children. Pediatric blasts showed a significantly higher expression of Nec-2 (P=0.03), ULBP-1 (P=0.01) and ULBP-3 (P=0.04) compared to adult cells. The differential expression of these ligands between adults and children was confined to B-lineage acute lymphoblastic leukemia with no known molecular alterations. Within molecularly defined subgroups of patients, a high surface expression of NKG2D and DNAM1 ligands was found on BCR-ABL(+) blasts, regardless of patient age. Accordingly, BCR-ABL(+) blasts proved to be significantly more susceptible to natural killer-dependent lysis than B-lineage blasts without molecular aberrations (P=0.03). Cytotoxic tests performed in the presence of neutralizing antibodies indicated a pathway of acute lymphoblastic leukemia cell recognition in the setting of the Nec-2/DNAM-1 interaction. These data provide a biological explanation of the different roles played by alloreactive natural killer cells in pediatric versus adult acute lymphoblastic leukemia and suggest that new natural killer-based strategies targeting specific subgroups of patients, particularly those BCR-ABL(+), are worth pursuing further. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658822      PMCID: PMC4077088          DOI: 10.3324/haematol.2013.101931

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  43 in total

Review 1.  Targeted immunotherapy for acute myeloid leukemia.

Authors:  Sumithira Vasu; Michael A Caligiuri
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-11       Impact factor: 3.020

Review 2.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

3.  Natural killer cell signaling pathways.

Authors:  Eric Vivier; Jacques A Nunès; Frédéric Vély
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

4.  Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Authors:  Marco Vignetti; Paola Fazi; Giuseppe Cimino; Giovanni Martinelli; Francesco Di Raimondo; Felicetto Ferrara; Giovanna Meloni; Achille Ambrosetti; Giovanni Quarta; Livio Pagano; Giovanna Rege-Cambrin; Loredana Elia; Raffaello Bertieri; Luciana Annino; Robin Foà; Michele Baccarani; Franco Mandelli
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

5.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

6.  How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

Review 7.  Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.

Authors:  Lorenzo Moretta; Franco Locatelli; Daniela Pende; Emanuela Marcenaro; Maria Cristina Mingari; Alessandro Moretta
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

8.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes.

Authors:  A Shibuya; D Campbell; C Hannum; H Yssel; K Franz-Bacon; T McClanahan; T Kitamura; J Nicholl; G R Sutherland; L L Lanier; J H Phillips
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

Review 9.  NK cell receptors and their ligands in leukemia.

Authors:  S Verheyden; C Demanet
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

10.  Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells.

Authors:  Franco Locatelli; Daniela Pende; Maria C Mingari; Alice Bertaina; Michela Falco; Alessandro Moretta; Lorenzo Moretta
Journal:  Front Immunol       Date:  2013-02-01       Impact factor: 7.561

View more
  26 in total

1.  Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.

Authors:  Nicole Liberio; Haley Robinson; Melodee Nugent; Pippa Simpson; David A Margolis; Subramaniam Malarkannan; Carolyn Keever-Taylor; Monica S Thakar
Journal:  Pediatr Blood Cancer       Date:  2019-07-31       Impact factor: 3.167

Review 2.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

3.  Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Authors:  Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

4.  KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.

Authors:  Lena Oevermann; Sebastian U Michaelis; Markus Mezger; Peter Lang; Jacek Toporski; Alice Bertaina; Marco Zecca; Lorenzo Moretta; Franco Locatelli; Rupert Handgretinger
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

Review 5.  The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia.

Authors:  Alireza Zafarani; Mahsa Taghavi-Farahabadi; Mohammad Hossein Razizadeh; Mohammad Reza Amirzargar; Mansoure Mansouri; Mohammad Mahmoudi
Journal:  Stem Cell Rev Rep       Date:  2022-08-22       Impact factor: 6.692

6.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

7.  Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.

Authors:  Kristin M Page; Myriam Labopin; Annalisa Ruggeri; Gerard Michel; Cristina Diaz de Heredia; Tracey O'Brien; Alessandra Picardi; Mouhab Ayas; Henrique Bittencourt; Ajay J Vora; Jesse Troy; Carmen Bonfim; Fernanda Volt; Eliane Gluckman; Peter Bader; Joanne Kurtzberg; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-21       Impact factor: 5.742

8.  Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia.

Authors:  Michael R Verneris; Jeffrey S Miller; Katherine C Hsu; Tao Wang; Jennifer A Sees; Sophie Paczesny; Hemalatha Rangarajan; Dean A Lee; Stephen R Spellman; Stephanie J Lee
Journal:  Blood Adv       Date:  2020-04-14

9.  The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.

Authors:  R H Rouce; H Shaim; T Sekine; G Weber; B Ballard; S Ku; C Barese; V Murali; M-F Wu; H Liu; E J Shpall; C M Bollard; K R Rabin; K Rezvani
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

10.  NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.

Authors:  Patrick Schlegel; Kerstin Ditthard; Peter Lang; Markus Mezger; Sebastian Michaelis; Rupert Handgretinger; Matthias Pfeiffer
Journal:  J Immunol Res       Date:  2015-07-08       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.